Today: 21 July 2026
Browse Category

ASX:CSL 2 December 2025 - 26 December 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

That finish matters for two reasons. First, it keeps CSL hovering close to its 52‑week low after a bruising year for one of Australia’s most widely held “quality compounder” names. Investing.com Second, it lands amid a wider re‑rating story investors have been living through since August: CSL is no longer being priced like a smooth, predictable growth machine—markets are treating it like a business in the middle of a complicated reset.
24 December 2025
·
Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia’s sharemarket kicked off the pre-Christmas week in upbeat fashion on Monday, with the S&P/ASX 200 trading higher into the afternoon as miners and energy stocks led broad-based gains. By early afternoon in Sydney, the benchmark was up about 0.9% around 8,701 points, with most sectors in the green and risk appetite supported by stronger global leads and a fresh surge in commodities. ABC+1
22 December 2025
········
CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL Limited heads into the final stretch of 2025 with its share price still under pressure—but with a growing stack of “things that matter” piling up beneath the surface: a sizeable on‑market buyback steadily absorbing stock, a major US manufacturing investment designed to reinforce its plasma-therapy moat, and a high-profile strategic reset that’s trying to simplify a complex, three‑engine biotech into something the market can price with less guesswork.
21 December 2025
·
CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited has spent 2025 reminding the market of an awkward truth: even “defensive” healthcare giants can deliver very non-defensive share price swings. After a year dominated by vaccine-market volatility, a reshaped strategy for CSL Seqirus, and investor nerves around China pricing, the stock heads into late December with a familiar question hanging in the air—is CSL Limited stock a bruised blue-chip bargain, or a business still working through its hardest chapter? TradingView+1
20 December 2025
CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited spent much of 2025 reminding investors of a brutal truth: even world-class biopharma franchises can get whacked when costs, policy, and sentiment all lean the wrong way at the same time. On 18 December 2025, the CSL share price was A$174.57, up 0.68% on the day after trading between A$171.64 and A$174.65. Intelligent Investor
18 December 2025
·
CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited shares ended Wednesday, December 17, 2025 lower as investors digested a fresh on-market buyback update and the lingering impact of broker downgrades that have reshaped sentiment around one of Australia’s most widely held healthcare names. CSL closed at A$172.77, down 2.47% on the day, after trading between A$172.75 and A$176.83 with roughly 800,720 shares changing hands. Investing.com
17 December 2025
CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL Limited is back in the spotlight on Monday, 15 December 2025 — and not for the reasons long-term holders are used to. After years of being treated as the ASX’s “defensive growth” heavyweight, CSL stock is now trading around the A$180 level, with investors weighing fresh broker caution against a still-solid consensus view that the shares are undervalued. Investing.com+1
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene therapy HEMGENIX, and fresh scrutiny on Australia’s onshore vaccine manufacturing deals tied to CSL Seqirus — all while CSL continues to steadily mop up stock through its A$750 million on-market buyback. Global Newsroom | CSL+4Yahoo Finance+4Intelligent Investor+4
14 December 2025
··
CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL Limited shares finished Friday’s session firmly higher, with the biotech giant benefiting from a broader rebound in Australian healthcare stocks and fresh attention on two CSL-specific threads: its ongoing on-market share buyback and the latest long-term durability data for its hemophilia B gene therapy, HEMGENIX. Market Index+2CSL Limited+2
13 December 2025
··
CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited stock is back in the spotlight on December 12, 2025, with fresh disclosure showing the company’s on-market share buyback is still running at pace—while investors continue weighing a messy mix of catalysts: vaccine-market volatility, government scrutiny of Australia’s “sovereign manufacturing” deals, and a pipeline story that just landed in The New England Journal of Medicine.
12 December 2025
·
CSL Limited (ASX:CSL) Share Price Near $180: Latest News, Analyst Forecasts and 2026 Outlook as at 10 December 2025

CSL Limited (ASX:CSL) Share Price Near $180: Latest News, Analyst Forecasts and 2026 Outlook as at 10 December 2025

CSL Limited, the Melbourne‑based plasma and vaccines giant, is finishing 2025 under intense scrutiny from investors, regulators and politicians alike. As of the afternoon of 10 December 2025, CSL shares are trading around A$180–182, after closing at about A$181.82 on 9 December and slipping intraday today to roughly A$181.Intelligent Investor+1
10 December 2025
·
CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

On 5 December 2025, the ASX healthcare heavyweight is trading near multi‑year lows after a brutal few months of restructuring, a guidance cut and a delayed vaccines spin‑off. At the same time, CSL is ramping up a large on‑market buyback, opening a $1 billion vaccine and antivenom plant in Melbourne and reiterating medium‑term profit growth targets. Global Newsroom | CSL+1
5 December 2025
···
CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

CSL Limited, the Australian biotech heavyweight, is trading around A$183 per share on 4 December 2025 after one of the most bruising years in its modern history. The company has delivered solid profit growth, announced thousands of job cuts, delayed a major spin‑off, launched a A$750 million buy‑back and opened a A$1 billion cell‑based vaccine and antivenom plant in Melbourne – all while its share price has fallen by roughly a third. Intelligent Investor+2Global Newsroom | CSL+2
4 December 2025
·
CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

CSL Limited’s share price has spent most of 2025 in the sin bin, but behind the drawdown sits a mix of solid earnings growth, a radical restructuring, a forthcoming spin‑off of its vaccines arm and fresh news today about a major new vaccine plant and an active on‑market buyback. Together, these developments are reshaping the investment story for one of the ASX’s most important healthcare names.
2 December 2025
·
1 2 3 4
Go toTop